The cohorts treated with anti-CD19 drugs had higher odds for all-grade (OR, 2.7; 95% CI, 1.0–7.7; P = 0.057) ICANS than cohorts treated with anti-BCMA drugs, with borderline significance.
← all excerpts
Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis.
1
—
—